Abstract 1509PD
Background
Stage III TET represents a heterogeneous population and their optimal approach remains unclear; most of the available literature is composed of small series spanned over extended periods of time. RYTHMIC (Réseau tumeurs THYMiques et Cancer) is a French nationwide network for TET with the objective of territorial coverage by regional expert centers and systematic discussion of patients management at national tumor board. We reviewed our experience in stage III thymic tumors in order to evaluate the value of tumor board recommendations and multidisciplinary approach.
Methods
We conducted a retrospective analysis of patients (pts) with stage III TET discussed at the RYTHMIC tumor board from January 2012 to December 2015. Clinical, pathologic and surgical data were prospectively collected in a central database. Survival rates were based on Kaplan-Meier estimation. Cox proportional hazard models were used to evaluate prognostic factors for disease free survival (DFS) and overall survival (OS).
Results
150 pts were included in the analysis. Median age was 64 years [18 – 91], 56% males, thymoma A-B2/ B3-thymic carcinoma in 52% and 47% respectively; 12% presented with autoimmune disorder (76% myasthenia). Local treatment was surgery in 134 pts (90%) followed by radiotherapy (RT) in 90 pts; 26 pts received preoperative chemotherapy (CT). Complete resection rate (R0) was 53%. Among 38 pts considered non-surgical candidates at diagnosis, 26 pts became resectable after induction CT with a R0 rate of 58%; 12 pts received CT-RT and/or CT as primary treatment. Recurrence rate was 38% (n = 57), first sites were pleural (n = 32) and lung (n = 12). The 5-year OS and DFS were 88% and 32% respectively. Gender (p = 0.04), histology (p = 0.02) and surgery (p
Conclusions
Surgery followed by radiotherapy improves outcome irrespectively of R0. Stage III TET not candidate to surgery should be reassessed for resection after induction chemotherapy.
Clinical trial identification
Legal entity responsible for the study
N/A
Funding
RYTHMIC
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Small cell lung carcinoma harbors targetable alterations including MYCL1 fusions responding to aurora kinase inhibitor
Presenter: Siraj Ali
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC)
Presenter: Taofeek Owonikoko
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Presentation
Webcast
Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC)
Presenter: Martin Reck
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Patient-reported outcomes (PROs) and impact of lactate dehydrogenase (LDH) levels on outcomes in a phase 3 trial (NGR015) with best investigator choice (BIC) plus or minus NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM)
Presenter: Vanesa Gregorc
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Pathological central review of 400 thymic epithelial tumors (TET): The national network RYTHMIC experience
Presenter: Thierry Molina
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer
Presenter: Patrick Forde
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Presentation
Webcast
Multi-centre randomized controlled study comparing adjuvant vs neo-adjuvant chemotherapy with docetaxel plus carboplatin in resectable stage IB to IIIA NSCLC: final results of CSLC0501
Presenter: Yi-Long Wu
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Presentation
Webcast
Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study
Presenter: Gianpiero Fasola
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Invited discussant LBA41 and abstract 1178O
Presenter: Paul Baas
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Presentation
Webcast
Invited discussant abstracts 1509PD and 1510PD
Presenter: Enrico Ruffini
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Presentation
Webcast